Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study (TRAIN-3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03820063
Recruitment Status : Recruiting
First Posted : January 29, 2019
Last Update Posted : July 10, 2020
Sponsor:
Collaborators:
Roche Pharma AG
BOOG Study Center
Information provided by (Responsible Party):
Borstkanker Onderzoek Groep

Tracking Information
First Submitted Date  ICMJE January 25, 2019
First Posted Date  ICMJE January 29, 2019
Last Update Posted Date July 10, 2020
Actual Study Start Date  ICMJE February 27, 2019
Estimated Primary Completion Date February 1, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 25, 2019)		 Event free survival at three years [ Time Frame: 3 years ]
Number of patients without progression of disease recurrence, second primary or death
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 8, 2020)
  • Overall survival at three years [ Time Frame: 3 years ]
    Number of patients alive at three years
  • Pathologic complete response in breast and axilla [ Time Frame: an average of 6 months ]
    Number of patients with absence of invasive tumor cells in breast and axilla at surgery
  • Radiologic complete response [ Time Frame: an average of 6 months ]
    Number of patients with absence of pathologic enhancement on MRI
  • Number of neoadjuvant chemotherapy cycles administered [ Time Frame: an average of 1 year ]
    Number of neoadjuvant chemotherapy cycles administered per patient
  • Number of radical and non-radical resections [ Time Frame: an average of 6 months ]
    Number of patients with radical and non-radical resections
  • Incidence and severity of adverse events [ Time Frame: an average of 1 year ]
    Number of patients with toxicity grade >= 3 (CTCAE v5.0) until 30 days after last adjuvant administration
  • Incidence and severity of cardiotoxicity and neuropathy [ Time Frame: an average of 1 year ]
    Number of patients with cardiotoxicity and neuropathy grade >= 2 (CTCAE v5.0) until 30 days after last adjuvant administration
  • Incidence of symptomatic LVSD (heart failure), [ Time Frame: an average of 1 year ]
    Number of patients with an asymptomatic decline in LVEF requiring treatment or leading to discontinuation of pertuzumab and Herceptin, or a decrease ≥10 percentage points from baseline to a LVEF <50%
  • Grade ≥3 laboratory test abnormalities [ Time Frame: an average of 1 year ]
    Number of patients with Grade ≥3 laboratory test abnormalities
  • Incidence of number of tumor positive Vacuum Assisted Core Biopsy [ Time Frame: an average 6 months ]
    Number of patients with tumor present at Vacuum Assisted Core Biopsy at the moment of radiological complete response on MRI
Original Secondary Outcome Measures  ICMJE
 (submitted: January 25, 2019)
  • Overall survival at three years [ Time Frame: 3 years ]
    Number of patients alive at three years
  • Pathologic complete response in breast and axilla [ Time Frame: an average of 6 months ]
    Number of patients with absence of invasive tumor cells in breast and axilla at surgery
  • Radiologic complete response [ Time Frame: an average of 6 months ]
    Number of patients with absence of pathologic enhancement on MRI
  • Number of neoadjuvant chemotherapy cycles administered [ Time Frame: an average of 1 year ]
    Number of neoadjuvant chemotherapy cycles administered per patient
  • Number of radical and non-radical resections [ Time Frame: an average of 6 months ]
    Number of patients with radical and non-radical resections
  • Incidence and severity of adverse events [ Time Frame: an average of 1 year ]
    Number of patients with toxicity grade >= 3 (CTCAE v5.0) until 30 days after last adjuvant administration
  • Incidence and severity of cardiotoxicity and neuropathy [ Time Frame: an average of 1 year ]
    Number of patients with cardiotoxicity and neuropathy grade >= 2 (CTCAE v5.0) until 30 days after last adjuvant administration
  • Incidence of symptomatic LVSD (heart failure), [ Time Frame: an average of 1 year ]
    Number of patients with an asymptomatic decline in LVEF requiring treatment or leading to discontinuation of pertuzumab and Herceptin, or a decrease ≥10 percentage points from baseline to a LVEF <50%
  • Grade ≥3 laboratory test abnormalities [ Time Frame: an average of 1 year ]
    Number of patients with Grade ≥3 laboratory test abnormalities
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study
Official Title  ICMJE Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study
Brief Summary This is a multicenter, single arm, phase II study evaluating the efficacy of image-guided de-escalating neoadjuvant treatment with paclitaxel, Herceptin® (trastuzumab), carboplatin, and pertuzumab (PTC-Ptz) in stage II-Ill HER2-positive breast cancer.
Detailed Description

High pathological complete response (pCR)-rates are seen using different neoadjuvant chemotherapy schedules with trastuzumab and pertuzumab in HER2-positive stage II - III breast cancer patients. Total pCR rates in breast and axilla have been described as high as 64%, and with an even higher rate of >80% in patients with HER2-positive and hormone receptor (HR) negative tumors. PCR is associated with better long-term outcomes in patients with HER2-positive breast cancer. Three year progression-free survival ranges between 85-90%. Neoadjuvant treatment of HER2-positive breast cancer typically consists of six to nine cycles of treatment. Longer duration of treatment is associated with higher pCR-rates but gives more toxicity. Pathological complete responses are sometimes seen after only 10-12 days of neoadjuvant treatment. It is therefore important to investigate which patients can safely be treated with less than six cycles of chemotherapy and who requires more than six cycles for maximum activity.

The radiologic response of a breast tumor after neoadjuvant therapy is predictive of the pathologic response, although the accuracy differs between breast cancer subtypes. It is hypothesized that patients with an early complete radiologic response may not benefit from additional chemotherapy and can be referred for early surgery. Patients who have not achieved pCR after early surgery despite radiologic complete response (rCR) are candidates for further adjuvant chemotherapy to complete the initially planned number of treatment cycles and maintain maximum treatment activity. Imaged guided de-escalation in which the number of treatment cycles is determined by the radiologic response could thus reduce toxicity in neoadjuvant treatment while maintaining activity.

This study will evaluate the efficacy of image-guided de-escalation of neoadjuvant chemotherapy in patients with HER2-positive breast cancer.

To maintain efficacy, patients who do not achieve pCR will complete a total of nine cycles taxane-containing chemotherapy followed by 14 cycles of treatment with adjuvant T-DM1. Patients who achieve early pCR will continue treatment with Herceptin® and pertuzumab to complete one full year of treatment.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:
neoadjuvant courses PTC-Ptz; adjuvant courses Ptz (pCR) or T-DM1 (non-pCR)
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Breast Cancer
Intervention  ICMJE Drug: PTC-Pz
  • Paclitaxel 80mg/m2 administered intravenously on day 1 and day 8
  • Herceptin® 6mg/kg administered intravenously on day 1 (loading dose 8mg/kg) or Herceptin® administered subcutaneously 600mg on day 1
  • Carboplatin AUC 6mg•ml/min administered intravenously on day 1
  • Pertuzumab 420mg administered intravenously on day 1 (loading dose 840mg)
  • Treatment cycles are repeated on day 22

In case of non pCR; Adjuvant T-DM1, 3.6mg/kg Q 22 days, for 14 cycles.
Study Arms  ICMJE Experimental: PTC-Pz
  • Paclitaxel 80mg/m2 administered intravenously on day 1 and day 8
  • Herceptin® 6mg/kg administered intravenously on day 1 (loading dose 8mg/kg) or Herceptin® administered subcutaneously 600mg on day 1
  • Carboplatin AUC 6mg•ml/min administered intravenously on day 1
  • Pertuzumab 420mg administered intravenously on day 1 (loading dose 840mg)
  • Treatment cycles are repeated on day 22

Patients who do not achieve pCR will complete a total of nine cycles taxane-containing chemotherapy followed by 14 cycles of treatment with adjuvant T-DM1.

Intervention: Drug: PTC-Pz
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: January 25, 2019)		 462
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE February 1, 2032
Estimated Primary Completion Date February 1, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Histologically confirmed primairy infiltrating breast cancer.
  2. Stage II or Ill disease.
  3. Overexpression and/or amplification of HER2 in an invasive component of the core biopsy.
  4. Age <:18
  5. ECOG Group performance status
  6. LVEF >50% measured by echocardiography, MRI or MUGA
  7. Known HR-status ( in percentages)

Exclusion Criteria:

  1. Previous radiation therapy of chemotherapy
  2. Pregnancy or breastfeeding
  3. Evidence of distant metastases
  4. Evidence of bilateral infiltrating breast cancer
  5. Concurrent anti-cancer treatment or another investigational drug
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Anna van der Voort, MD +3120512 ext 9111 a.vd.voort@nki.nl
Contact: G S Sonke, MD train3@nki.nl
Listed Location Countries  ICMJE Netherlands
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03820063
Other Study ID Numbers  ICMJE BOOG 2018-01
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Borstkanker Onderzoek Groep
Study Sponsor  ICMJE Borstkanker Onderzoek Groep
Collaborators  ICMJE
  • Roche Pharma AG
  • BOOG Study Center
Investigators  ICMJE
Principal Investigator: G S Sonke, MD NKI-AvL
Study Director: A E van Leeuwen- Stok, PhD BOOG Study Center
PRS Account Borstkanker Onderzoek Groep
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP